Skip to main content

Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.

Publication ,  Journal Article
O'Malley, PG; Arnold, MJ; Kelley, C; Spacek, L; Buelt, A; Natarajan, S; Donahue, MP; Vagichev, E; Ballard-Hernandez, J; Logan, A; Thomas, L ...
Published in: Ann Intern Med
November 17, 2020

DESCRIPTION: In June 2020, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) released a joint update of their clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in adults. This synopsis describes the major recommendations. METHODS: On 6 August to 9 August 2019, the VA/DoD Evidence-Based Practice Work Group (EBPWG) convened a joint VA/DoD guideline development effort that included clinical stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions, systematically searched and evaluated the literature (English-language publications from 1 December 2013 to 16 May 2019), and developed 27 recommendations and a simple 1-page algorithm. The recommendations were graded by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. RECOMMENDATIONS: This synopsis summarizes key features of the guideline in 7 crucial areas: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional tests for risk prediction, primary and secondary prevention, laboratory testing, physical activity, and nutrition.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 17, 2020

Volume

173

Issue

10

Start / End Page

822 / 829

Location

United States

Related Subject Headings

  • Secondary Prevention
  • Risk Assessment
  • Practice Guidelines as Topic
  • Medication Adherence
  • Hyperlipidemias
  • Hypercholesterolemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Exercise
 

Citation

APA
Chicago
ICMJE
MLA
NLM
O’Malley, P. G., Arnold, M. J., Kelley, C., Spacek, L., Buelt, A., Natarajan, S., … Downs, J. R. (2020). Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med, 173(10), 822–829. https://doi.org/10.7326/M20-4648
O’Malley, Patrick G., Michael J. Arnold, Cathy Kelley, Lance Spacek, Andrew Buelt, Sundar Natarajan, Mark P. Donahue, et al. “Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.Ann Intern Med 173, no. 10 (November 17, 2020): 822–29. https://doi.org/10.7326/M20-4648.
O’Malley PG, Arnold MJ, Kelley C, Spacek L, Buelt A, Natarajan S, Donahue MP, Vagichev E, Ballard-Hernandez J, Logan A, Thomas L, Ritter J, Neubauer BE, Downs JR. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2020 Nov 17;173(10):822–829.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

November 17, 2020

Volume

173

Issue

10

Start / End Page

822 / 829

Location

United States

Related Subject Headings

  • Secondary Prevention
  • Risk Assessment
  • Practice Guidelines as Topic
  • Medication Adherence
  • Hyperlipidemias
  • Hypercholesterolemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • General & Internal Medicine
  • Exercise